Svetlana N. Orlova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Svetlana N. Orlova has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Natalia Yurievna Pshenichnaya
Central Research Institute of Epidemiology
3 shared publications - Artem A. Poromov
Laboratory of Experimental Virology, Mechnikov Research Institute of Vaccines and Sera, 105064 Moscow, Russia
2 shared publications - Denis V. Usenko
Central Research Institute of Epidemiology
2 shared publications - Elena P. Tikhonova
Voino-Yasenetsky Krasnoyarsk State Medical University
2 shared publications - Irina Anatolievna Leneva
Laboratory of Experimental Virology, Mechnikov Research Institute of Vaccines and Sera, 105064 Moscow, Russia
2 shared publications - Vladimir A. Petrov
Obninsk Institute for Nuclear Power Engineering
2 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 14 (2)
Umifenovir (Arbidol) and acute rotavirus gastroenteritis: antiviral activity, mechanism of action, review and meta-analysis of clinical studies
Умифеновир (Арбидол) и острый ротавирусный гастроэнтерит: противовирусная активность, механизм действия, обзор и метаанализ клинических исследований
- 1 January 2025
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 14 (2)
Open AccessUmifenovir (Arbidol) and acute rotavirus gastroenteritis: antiviral activity, mechanism of action, review and meta-analysis of clinical studies
Умифеновир (Арбидол) и острый ротавирусный гастроэнтерит: противовирусная активность, механизм действия, обзор и метаанализ клинических исследований
- Open Access
- 1 January 2024
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 13 (4)
The results of the All-Russian multicenter study of the use of the antitussive drug Codelac® Broncho in patients with productive cough
Результаты Всероссийского многоцентрового исследования применения комбинированного препарата Коделак Бронхо у пациентов с продуктивным кашлем
- 1 January 2024
- Published by Geotar-Media Publishing Group in Infectious diseases: News, Opinions, Training
- Vol. 13 (4)
Open AccessThe results of the All-Russian multicenter study of the use of the antitussive drug Codelac® Broncho in patients with productive cough
Результаты Всероссийского многоцентрового исследования применения комбинированного препарата Коделак Бронхо у пациентов с продуктивным кашлем
- Open Access
- 15 November 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (11) , 1306-1315
Pharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020
Aim. An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness. Materials and methods. The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of Russia. The number of men and women was equal, mean age 48.718.1 (median 50). Patients with moderate COVID-19 (85%) versus mild COVID-19 (15%) were characterized by higher age (median 54 vs 21 years; p0.001), higher body mass index (27.8 vs 23.4; p0.001), prevalence of chronic diseases (75.3% vs 8.5%; p0.001), including circulatory system diseases (37.8%). Moderate COVID-19 characterized higher intoxication (10.86.1 vs 4.22.7 days; p0.001) and catarrhal symptoms duration (10.25.4 vs 6.14.1 days; p0.001). Results. During hospitalization 92% of the patients received AVT, 77% antibiotics, and 16% corticosteroids. Umifenovir therapy resulted in a significant reduction of intoxication (8.75.5 vs 11.75.5 days; p0.001) and catarrhal symptoms duration (8.85.1 vs 12.04.9 days; p0.001) compared to the group without AVT. The usage of INF reduced intoxication symptoms compared with the group without AVT (8.97.5 vs 11.75.5; p0.05). Therapy with hydroxychloroquine, imidazolylethanamide pentandioic acid, and lopinavir + ritonavir combination did not affect the course of COVID-19. Most of adverse reactions were related to antibiotics. Conclusion. Umifenovir therapy and inclusion of interferon in AVT regimens was associated improvement in the clinical manifestation of the disease among patients.
- 15 November 2021
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 93 (11) , 1306-1315
Open AccessPharmacoepidemiological research of COVID-19 in the Russian Federation EGIDA-2020
Aim. An analysis of coronavirus infection in Russia and evaluation of different AVT regimens effectiveness. Materials and methods. The study involved a retrospective analysis of 1082 patient records with laboratory-confirmed COVID-19 in 17 regions of Russia. The number of men and women was equal, mean age 48.718.1 (median 50). Patients with moderate COVID-19 (85%) versus mild COVID-19 (15%) were characterized by higher age (median 54 vs 21 years; p0.001), higher body mass index (27.8 vs 23.4; p0.001), prevalence of chronic diseases (75.3% vs 8.5%; p0.001), including circulatory system diseases (37.8%). Moderate COVID-19 characterized higher intoxication (10.86.1 vs 4.22.7 days; p0.001) and catarrhal symptoms duration (10.25.4 vs 6.14.1 days; p0.001). Results. During hospitalization 92% of the patients received AVT, 77% antibiotics, and 16% corticosteroids. Umifenovir therapy resulted in a significant reduction of intoxication (8.75.5 vs 11.75.5 days; p0.001) and catarrhal symptoms duration (8.85.1 vs 12.04.9 days; p0.001) compared to the group without AVT. The usage of INF reduced intoxication symptoms compared with the group without AVT (8.97.5 vs 11.75.5; p0.05). Therapy with hydroxychloroquine, imidazolylethanamide pentandioic acid, and lopinavir + ritonavir combination did not affect the course of COVID-19. Most of adverse reactions were related to antibiotics. Conclusion. Umifenovir therapy and inclusion of interferon in AVT regimens was associated improvement in the clinical manifestation of the disease among patients.
- 1 January 2021
- Published by Vestnik Ivanovskoj medicinskoj akademii, Ivanovo State Medical Academy in Bulletin of the Ivanovo State Medical Academy
- Vol. 26 (1) , 21-27
RISK FACTORS FOR UNFAVORABLE COURSE OF NEW CORONAVIRUS INFECTION
- 1 January 2021
- Published by Vestnik Ivanovskoj medicinskoj akademii, Ivanovo State Medical Academy in Bulletin of the Ivanovo State Medical Academy
- Vol. 26 (1) , 21-27
RISK FACTORS FOR UNFAVORABLE COURSE OF NEW CORONAVIRUS INFECTION
- 29 May 2007
- No. 2,p. 7-9
[Influence of environmental and climatic factors on the incidence and course of stenosing laryngotracheitis in children with acute respiratory diseases].
A clear correlation was found between the development of stenosing laryngotracheitis (SLT) in the presence of viral infection, its severity, and the environment well-being of an area where a child resides. The level of environmental pollution and the interaction of environmental factors and weather-climatic ill-being, which vary with time and have regional features, adversely affect the course of SLT and require mandatory correction during complex therapy and seasonal antirecurrent treatment. The increase in the incidence of childhood SLT may be a biological indicator of the environmental ill-being of a region.
- 29 May 2007
- No. 2,p. 7-9
[Influence of environmental and climatic factors on the incidence and course of stenosing laryngotracheitis in children with acute respiratory diseases].
A clear correlation was found between the development of stenosing laryngotracheitis (SLT) in the presence of viral infection, its severity, and the environment well-being of an area where a child resides. The level of environmental pollution and the interaction of environmental factors and weather-climatic ill-being, which vary with time and have regional features, adversely affect the course of SLT and require mandatory correction during complex therapy and seasonal antirecurrent treatment. The increase in the incidence of childhood SLT may be a biological indicator of the environmental ill-being of a region.
- 1 January 2007
- No. 2,p. 16-9
[Some mechanisms of a recurrent course of stenosing laryngotracheitis in children].
Staged development of dysbiotic disturbance of the upper airways was revealed in children suffering from stenosing laryngotracheitis in the presence of viral infection. Chronic persistent virus-bacterial inflammation of respiratory tract mucosa and resultant hypersensitivity of the airways produce chronic defects in lung ventilation in patients with recurrent stenosing laryngotracheitis. High sensitivity of the airways to histamine is related to bioelectric activity of the brain characterized by dominant irritation of the mesencephalo-diencephalic structures. Typical features of the curve flow-volume and paradoxic result of the test with broncholytic drugs verified tracheobronchial dyskinesia in patients with stenosing laryngotracheitis. Such dyskinesia promoted the recurrent disease with transformation into bronchial asthma.
- 1 January 2007
- No. 2,p. 16-9
[Some mechanisms of a recurrent course of stenosing laryngotracheitis in children].
Staged development of dysbiotic disturbance of the upper airways was revealed in children suffering from stenosing laryngotracheitis in the presence of viral infection. Chronic persistent virus-bacterial inflammation of respiratory tract mucosa and resultant hypersensitivity of the airways produce chronic defects in lung ventilation in patients with recurrent stenosing laryngotracheitis. High sensitivity of the airways to histamine is related to bioelectric activity of the brain characterized by dominant irritation of the mesencephalo-diencephalic structures. Typical features of the curve flow-volume and paradoxic result of the test with broncholytic drugs verified tracheobronchial dyskinesia in patients with stenosing laryngotracheitis. Such dyskinesia promoted the recurrent disease with transformation into bronchial asthma.